Clearside Biomedical Inc [CLSD] stock is trading at $1.67, saw in change for the day. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLSD shares have gain 20.14% over the last week, with a monthly amount glided 21.01%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on July 29, 2021, and set its price target to $10. On May 13, 2020, ROTH Capital initiated with a Buy rating and assigned a price target of $8 on the stock. Needham downgraded its rating to a Hold. Stifel downgraded its rating to a Hold. JP Morgan downgraded its rating to Underweight for this stock on November 05, 2018. In a note dated November 05, 2018, Cowen downgraded an Market Perform rating on this stock.
Clearside Biomedical Inc [CLSD] stock has fluctuated between $0.65 and $1.74 over the past year. Clearside Biomedical Inc [NASDAQ: CLSD] shares were valued at $1.67 at the most recent close of the market.
Analyzing the CLSD fundamentals
Clearside Biomedical Inc [NASDAQ:CLSD] reported sales of 2.21M for the trailing twelve months, which represents a growth of 222.93%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -13.57%, Pretax Profit Margin comes in at -16.88%, and Net Profit Margin reading is -18.13%. To continue investigating profitability, this company’s Return on Assets is posted at -1.16, Equity is 35.51 and Total Capital is -1.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5967 points at the first support level, and at 1.5233 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8067, and for the 2nd resistance point, it is at 1.9433.
Ratios To Look Out For
For context, Clearside Biomedical Inc’s Current Ratio is 5.28. Also, the Quick Ratio is 5.28, while the Cash Ratio stands at 4.94. Considering the valuation of this stock, the price to sales ratio is 56.46.
Transactions by insiders
Recent insider trading involved WHITMORE BRADFORD T, 10% Owner, that happened on Feb 07 ’24 when 0.44 million shares were purchased. CEO, LASEZKAY GEORGE M completed a deal on Jan 19 ’24 to sell 18000.0 shares. Meanwhile, Chief Financial Officer Deignan Charles A. sold 12900.0 shares on Jan 19 ’24.
